Source comparison
CJC-1295 Study — Key Findings and Clinical Evidence: Comparison
CJC-1295 with DAC 6–8 days Once weekly or biweekly 6–13 days Teichman et al. phase I/II trials (2005, 2006) Sustained GH secretion with minimal dosing burden. Strongest clinical trial support for long-acting GHRH analogs Modified GRF (1-29) ~30 minutes 2–3× da
This comparison does not assign a generated winner or score.
- CJC-1295 with DAC
- 6–8 days
- Once weekly or biweekly
- 6–13 days
- Teichman et al. phase I/II trials (2005, 2006)
- Sustained GH secretion with minimal dosing burden. Strongest clinical trial support for long-acting GHRH analogs
- Modified GRF (1-29)
- ~30 minutes
- 2–3× daily
- 2–4 hours per dose
- Derivative research only. No dedicated clinical trials
- Short-acting pulse mimics natural GH secretion. Useful for protocols requiring circadian rhythm alignment but requires frequent administration
- Sermorelin
- ~10 minutes
- 1–2× daily
- 1–3 hours per dose
- Limited phase II data from 1990s
- Rapid degradation limits practical research utility. Largely replaced by more stable analogs
- Tesamorelin
- ~45 minutes
- Once daily
- 3–6 hours
- FDA-approved for HIV-associated lipodystrophy. Extensive phase III data
- Strongest regulatory approval status but designed for therapeutic use, not research optimization
- The CJC-1295 study data makes clear that DAC modification is the defining feature separating sustained from pulsatile GHRH agonists. For protocols requiring steady-state GH elevation. Such as metabolic studies tracking fat oxidation or lean mass accretion over weeks. CJC-1295 with DAC offers the most consistent pharmacokinetic profile. For studies investigating pulsatile GH dynamics or circadian rhythm effects, Modified GRF (1-29) better mimics endogenous secretion patterns.